

DAFTAR PUSTAKA

- Agarwal A., Srivastara, K., Purb, S.K. & Chauhana, P.M.S. 2005. Synthesis of 4-pyrido-6-aryl-2-substituted amino pyrimidines as a new class of antimalarial agents. *Bioorg. Med. Chem.*, 13: 6226–6232.
- Alshawsh, M.A., Mothana, R.A., Al-shamahy, H.A., Alslami, S.F. & Lindequist, U. 2007. Assessment of antimalarial activity against *Plasmodium falciparum* and phytochemical screening of some Yemeni medicinal plants. *eCAM*:1-4. doi:10.1093/ecam/nem148, <http://creativecommons.org/licenses/by-nc/2.0/uk/>, diakses tanggal 30 April 2008.
- Anderson, M.M., O'Neill M.J., Phillipson J.D & Warhust, D.C. 1991. *In vitro* cytotoxicity of a series of quassinoid from *Brucea javanica* fruits against KB cells. *Planta Med.*, 57: 62-65.
- Ang, H.H., Chan, K.L. & Mak, J.W. 1995. Quantitative assessment of antimalarial activities from Malaysian *Plasmodium falciparum* isolates by modified *in vitro* microtechnique. *Antimicrob. Agents Chemother.*, 39:626-628.
- Angerhofer, C. K., Guinaudeau, H. & Wongpanich V. 1999. Antiplasmodial and activity of natural bisbenzyl isoquinoline alkaloids. *J. Nat. Prod.*, 62 (1): 59-66.
- Babalola, C.P, Adegoke, A.O, Ogunjinmi, M.A. & Osimosu, M.O. 2003. Determination of physicochemical properties of halofantrine. *Afr. J. Med. Med. Sci.*, 32(4): 357-359.
- Basco, L.K., Le Bras, J., Gillotin, C., Ringwald, P., Rabenjarson, E., Gimenez, F., Bouchaud, O., Farinotti, R. & Coulaud, J.P. 1991. Type RI resistance to halofantrine in West Africa. *Trop. Med. Parasitol.*, 42(4): 413-414.
- Basco, L.K. 2007. *Field Application of In Vitro Assays for the Sensitivity of Human Malaria Parasites to Antimalarial Drugs*. WHO, Geneva.
- Barnes, K.I., Chanda, P. & Barnaba, G.A. 2009. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. *Malaria Journal*, 8(Suppl 1):S8, doi:10.1186/1475-2875-8-S1-S8, <http://www.malariajournal.com/content/8/S1/S8>, diakses tanggal 29 Maret 2010.

- Biswas, S. 2002. Enhancement of antimalarial activity of chloramphenicol against Indian *Plasmodium falciparum* isolates *in vitro* by chloroquine. *Indian J. Malariol.*, 39: 26-33.
- Cowman, A.F., Karze, S., Galatis, D. & Culvenor, J.G. 1991. A P glycoprotein homologue of *Plasmodium falciparum* isolated on the digestive vacuole. *J. Cell Biol.*, 113: 1033–1045.
- Clarkson, C., Maharaj, V.J., Crouch, N.R., Grace, O.M., Pillay, P., Matsabisa, M.G., Bhagwandhin, N., Smith, P.J. & Folb, P.I. 2004. *In vitro* antiplasmodial activity of medicinal plants native to or naturalized in South Africa. *J. Ethnopharmacol.*, 92: 177–191.
- Creek, D.J., Chalmers, D.K., Charman, W.N. & Duke, B.J. 2008. Quantum chemical study of the intermediate complex required for iron-mediated reactivity and antimalarial activity of dispiro-1,2,4-trioxolanes. *J.M.G.M.*, 27: 394–400.
- Delarue-Cochin, S., Paunescu, E., Maes, L., Mouray, E., Sergheraert, C., Grellier, P. & Melnyk, P. 2008. Synthesis and antimalarial activity of new analogues of amodiaquine. *Eur. J. Med. Chem.*, 43: 252-260.
- Deloron, P., Le-Bras, J., Ramanamirija, J.A. & Coulanges, P. 1985. *Plasmodium falciparum* in Madagascar: *in vivo* and *in vitro* sensitivity to seven drugs. *Ann. Trop. Med. Parasitol.*, 79:357–365.
- Desjardin, R.E., Canfield, C.J. & Haynes, J.D. 1979. Quantitative assessment of antimalarial activity *in vitro* by a semi-automated microdulation technique. *Antimicrob. Agents Chemother.*, 16: 710-718.
- Djimde, A. & Lefevre, G. 2009. Understanding the pharmacokinetics of Coartem®. *Malaria Journal*, 8(Suppl 1):S4, doi:10.1186/1475-2875-8-S1-S4, <http://www.malariajournal.com/content/8/S1/S4>, diakses tanggal 29 Maret 2010.
- Dieckman, A. & Jung, A. 1986. Stage-specific sensitivity of *Plasmodium falciparum* to antifolates. *Z. Parasitenkd.*, 72(5): 591-594.
- Dondorp, A.M. Nosten, F., Yi, P., Das, D., Phyto, A.P., Tarning, J., Lwin, K.M., Arie, F., Hanpithakpong, W., Lee, S.J., Ringwald, P., Silamut, K., Imwong, M., Chotivanich, K., Lim, P., Herdman, T., An, S.S., Yeung, S., Singhasivanon, P., Day, N.P.J., Lindegardh, N., Socheat, D. & White, N.J. 2009. Artemisinin resistance in *Plasmodium falciparum* malaria. *N. Engl. J. Med.*, 361(5):455-467.

- Doyle, A. & Griffiths, J.B. 2000. *Cell and Tissue Culture for Medical Research*. John Wiley & Sons Ltd., England.
- Edmund, M.W. 2006. *Introduction to Clinical Pharmacology*. 5th ed., Mosby Elsevier, Missouri.
- Egan, T.J. 2004. Haemozoin formation as a target for the rational design of new antimalarials. *Drug Design Rev. – Online*, 1: 93-110.
- EMA (The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use), 2000, *Guidelines for the Conduct of Pharmacokinetic Studies in target Animal Species*. EMA, London.
- Falade, C. & Manyando, C. 2009. Safety profile of Coartem®: the evidence base. *Malaria Journal*, 8(Suppl 1):S6, doi:10.1186/1475-2875-8-S1-S6, <http://www.malariajournal.com/content/8/S1/S6>, diakses tanggal 29 Maret 2010.
- Farnert, A., Lindberg, J., Gil, P., Swedberg, G., Berqvist, Y., Thapar, M.M., Lindegardh, N., Berezcky, S., & Bjorkman, A. 2004. Evidence of *Plasmodium falciparum* malaria resistant to atovaquone and proguanil hydrochloride: case report. *B.M.J.*, 326: 628-629.
- Foote, S.J., Thompson, J.K., Cowman, A.F. & Kemp, D.J. 1989. Amplification of the multidrug resistance gene in some chloroquine resistant isolates of *P. falciparum*. *Cell*, 57: 921-930.
- Freshney, R.I. 2000. *Culture of Animal Cells, A Manual Basic Technique*. 4th ed. Wiley-Liss, New York.
- Fujioka, H. & Aikawa, M. 2002. Structure and life cycle, dalam P. Perlman & M. Troye-Blomberg (eds.): *Malaria immunology.*, Vol. 80: 1-26, Karger, Basel.
- Geary, T.G., Divo, A.A. & Jensen, J. B. 1989. Stage specific actions of antimalarial drugs on *Plasmodium falciparum* in culture. *Am. J. Trop. Med. Hyg.*, 40(3): 240-244.
- Griesbeck, A.G., El-Idreesy, T.T., Hoinck, L., Lexa, J. & Brunb, R. 2005. Novel spiroanellated 1,2,4-trioxanes with high in vitro antimalarial activities. *Bioorg. Med. Chem. Lett.*, 15: 595-597.
- Guarino, R.A. 2000. *New Drug Approval Process*, 3rd ed., Marcel Dekker, New York.

- Hadanu, R. 2004. Sintesis senyawa antimalaria (1)-N-Alkil-1,10 fenantrolinium dan 3-(2-hidroksietil)-2-metil-1,10-fenantrolin-4-ol. *Tesis*. Program Pascasarjana Universitas Gadjah Mada, Yogyakarta.
- Hadanu, R. 2007. Analisis hubungan kuantitatif struktur aktivitas (HKSA) dan sintesis senyawa baru antimalaria turunan 1,10-fenantrolin. *Disertasi*. Program Pascasarjana Universitas Gadjah Mada, Yogyakarta.
- Hansch, C. 1971. Quantitative Structure-Activity Relationship, in Ariens, *Drug Design*, I. Academic Press, New York.
- Hansch, C. & Dunn, W.J. 1972. Linear relationship between lipophilic character and biological activity of drugs. *J. Pharm. Sci.*, 61(1): 1-5.
- Harmita. 2004. Petunjuk pelaksanaan validasi metode dan cara perhitungannya. *Majalah Ilmu Kefarmasian*, I(3): 117 – 135.
- Hassan, A.M., Bjorkman, A. & Ashton. 1990. *In vitro* activity of artemisinin, its derivatives, and pyronaridine against different strains of *Plasmodium falciparum*. *Trans. R. Soc. Trop. Med. Hyg.*, 84: 635-637.
- Hay, R., Macy, M., Hamburger, A., Weinblatt, A. & Chen, T.R. 1983. *A Type Culture Collectin Catalogue of Strains II*. 4th Ed. ATCC, Maryland.
- Hidaka, K., Kimura, T., Ruben, A.J., Uemura, T., Kamiya, M., Kiso, A., Okamoto, T., Tsuchiya, Y., Hayashi, Y., Freire, E. & Kiso, Y. 2008. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. *Bioorg. Med. Chem.*, 16: 10049–10060.
- Houël, E., Bertani, S., Bourdy, G., Deharo, E., Jullian, V., Valentin, A., Chevalley, S. & Stiena, D. 2009. Quassinoid constituents of *Quassia amara* L. leaf herbal tea. Impact on its antimalarial activity and cytotoxicity. *J. Ethnopharmacol.*, 126: 114–118.
- Hughes, D. & Mehmet, H. (eds.), 2003. *Cell Proliferation & Apoptosis*. BIOS Scientific Publisher Limited, Oxford.
- Humberstone, A.J., Porter, C.J. & Charman, W.N. 1996. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. *J. Pharm. Sci.*, 85(5): 525-529.
- Jung, D.T. 1984. *Stripe*. College of Pharmacy University of Illinois, Chicago.

- Karbwang, J., Milton, K.A., Na Bangchang, K., Ward, S.A., Edwards, G. & Bunnag, D. 1991. Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. *Br. J. Clin. Pharmacol.*, 31(4): 484-487.
- Karbwang, J. & Na Bangchang, K., 1994, Clinical pharmacokinetics of halofantrine. *Clin. Pharmacokinet.*, 27(2): 104-119.
- Karcz, S.R., Galatis, D. & Cowman, A.F. 1993. Nucleotide binding properties of a P-glycoprotein homologue from *Plasmodium falciparum*. *Mol. Biochem. Parasitol.*, 58: 269-276.
- Keputusan Menteri Kesehatan Republik Indonesia. 2007. Pedoman Penatalaksanaan Kasus Malaria. Menteri Kesehatan Republik Indonesia, Jakarta.
- Kokwaro, G. 2009. Ongoing challenges in the management of malaria. *Malaria Journal*, 8(Suppl 1):S2, doi:10.1186/1475-2875-8-S1-S2, <http://www.malariajournal.com/content/8/S1/S2>, diakses tanggal 29 Maret 2010.
- Krogstad, D.J., Gluzman, I.Y., Kyle, D.E., Oduola, A.M.J., Martin, S.K., Milhous, W.K. & Schlesinger, P.H. 1987. Efflux of chloroquine from *Plasmodium falciparum* : mechanism of chloroquine resistance. *Science*, 238: 1283-1285.
- Labaiied, M., Dagan, A., Dellinger, Marc, Geze, M., Egee, S., Thomas, S.L., Wang, C., Gatt, S. & Grellier, P. 2004. Antiplasmodium activity of ceramide analogs. *Malaria Journal*, 3: 49, doi:10.1186/1475-2875-3-49, <http://www.malariajournal.com/content/3/1/49>, diakses tanggal 20 Mei 2006.
- Laihad, F.J. 1999. *Gebrak Malaria: Indonesia's Roll Back Malaria Initiative*. <http://www.mekong-malaria.org/mcis/mmf4/mmf4.htm>, diakses tanggal 27 April 2002.
- Le-Bras, J. & Deloron, P. 1983. *In vitro* study of drug sensitivity of *Plasmodium falciparum*: evaluation of a new semi-micro test. *Am. J. Trop. Med. Hyg.* 32:447-451.
- Le-Bras, J., Deloron, P., Hartmann, J.F., Coulanges, P., Dourado, H.V. & Larouze, B. 1984. Application of an *in vitro* semi-microtest to the study of drug sensitivity of 66 *Plasmodium falciparum* isolates from 15 countries. *Trans. R. Soc. Trop. Med. Hyg.*, 78: 485-488.

- Le-Bras, J. & Savel, J. 1987. La détermination de la chimiosensibilité de *Plasmodium falciparum*: méthodologie et interprétation [Determination of the drug sensitivity of *Plasmodium falciparum*: methodology and interpretation]. *Annales de Pédiatrie*, 34:349–356.
- Li, Y. & Wu, Y.L. 1998. How Chinese scientist discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives?. *Med. Trop.*, 58(suppl. 3): 9-12.
- Ljungström, I., Perlmann, H., Schlichtherle, M., Scherf, A., & Wahlgren, M. 2004. *Methods in Malaria Research*, 4th ed., MR4/ATCC Manassas, Virginia.
- Lullman, H., Mohr, K., Ziegler, A. & Bieger, D. 2000. *Color Atlas of Pharmacology*, 2nd ed. Thieme, New York.
- Makanga, M. & Krudsood, S. 2009. The clinical efficacy of artemether/lumefantrine (Coartem®). *Malaria Journal*, 8(Suppl 1):S5, doi:10.1186/1475-2875-8-S1-S5, <http://www.malariajournal.com/content/8/S1/S5>, diakses tanggal 29 Maret 2010.
- Martin, A. 1993. *Physical Pharmacy*. 4th ed., Lea & Febiger, Philadelphia.
- Martin, A., Swarbrick, J. & Cammarata, A. 1983. *Physical Pharmacy*. 3rd ed., Lea & Febiger, Philadelphia.
- Menteri Kesehatan dan Kesejahteraan Sosial. 2001. *Malaria Situation – Strategic Plan in Roll Back Malaria (Gebrak Malaria) 2001-2005*. Menteri Kesehatan dan Kesejahteraan Sosial, Jakarta.
- Mishra, K., Dash, A.P., Swain, B.K. & Dey, N. 2009a. Anti-malarial activities of *Andrographis paniculata* and *Hedyotis corymbosa* extracts and their combination with curcumin. *Malaria Journal*, 8:26, doi:10.1186/1475-2875-8-2, <http://www.malariajournal.com/content/8/1/26>, diakses tanggal 16 Oktober 2009.
- Mishra, A., Srivastava, K., Tripathi, R., Puri, S.K. & Batra, S. 2009b. Search for new pharmacophores for antimalarial activity. Part III: Synthesis and bioevaluation of new 6-thioureido-4-anilinoquinazolines. *Eur. J. Med. Chem.*, 44: 4404–4412.
- Mulja, H. & Suherman. 1995. *Analisis Instrumental*. Airlangga University Press, Surabaya.

- Mustofa. 2000. *In vitro* and *in vivo* activity of the divers of natural and synthetic antimalarial: Effect of potentialisator and the possibility of mechanism of actions. *Disertasi*, University of Montpellier I, France.
- Mustofa, 2003, Molekul antimalaria alami: Potensi dan tantangan pengembangannya sebagai obat baru malaria. *Majalah Obat Tradisional*, 8(26): 8-18.
- Mustofa. 2005. Pengembangan senyawa baru turunan fenantrolin-1,10 sebagai antimalaria. *Laporan Penelitian RUT X Bidang Kesehatan*. Kementerian Riset dan Teknologi RI Lembaga Ilmu Pengetahuan Indonesia, Jakarta.
- Mustofa. 2006. *In vitro* antiplasmodial activity and stage-specificity of 1,10-phenanthroline derivatives on *Plasmodium falciparum* cycles. *Berkala Ilmu Kedokteran*, 38(4), 175-182.
- Mustofa, Sholikhah, E.N. & Wahyuono, S. 2007. *In vitro* and *in vivo* antiplasmodial activity and cytotoxicity of extracts of *Phyllanthus niruri* L. herbs traditionally used to treat malaria. *Southeast Asian J. Trop. Med. Public Health*, 38(4): 609-615.
- Mustofa, Sholikhah, E.N. 2007. *In vitro* and *in vivo* antiplasmodial activity of fraction isolated from methanolic extract of Pasak Bumi (*Eurycoma longifolia* Jack) traditionally used to treat malaria in South Kalimantan. *Majalah Obat Tradisional*, 11(40): 25-30
- Mustofa, Yapi, A.D., Valentin, A. & Tahir, I. 2003. *In vitro* antiplasmodial activity of 1,10-phenanthroline derivatives and its Quantitative Structure-Activity Relationship. *Berkala Ilmu Kedokteran*, 35 (2): 67-74.
- Narla, R.K., Chen, C.L., Dong, Y. & Uckun, F.M. 2001a. *In vivo* antitumor activity of bis (4,7-dimethyl-1,10-phenanthroline) sulfatoxovanadium (IV) {METVAN [VO(SO₄) (Me₂-Phen)₂]}. *Clin. Cancer Res.*, 7: 2124-2133.
- Narla, R.K., Dong Y., Klis D. & Uckun, F.M. 2001b. Bis (4,7-dimethyl-1,10-phenanthroline) sulfatoxovanadium (IV) as a novel antileucemic agent with matrix metalloproteinase inhibitor activity. *Clin. Cancer Res.*, 7: 1094-1101.
- Neal, M.J. 1997., *Medical Pharmacology at a Glance*. 3rd ed., Blackwell Science, London.
- Nguyen-Dinh, P. & Trager, W. 1978. Chloroquine resistance produced *in vitro* in an African strain of human malaria. *Science*, 200 (4348): 1397-1398.

- Nguyen-Dinh, P. & Trager W. 1980. *Plasmodium falciparum in vitro*: determination of chloroquine sensitivity of three new strains by a modified 48-hour test. *Am. J. Tro. Med. Hyg.*, 29:339–342.
- Nguyen-Dinh, P. Hobbs, J.H. & Campbell, C.C. 1981. Assessment of chloroquine sensitivity of *Plasmodium falciparum* in Choluteca, Honduras. *Bull. World Health Organ.*, 59(4): 641–646.
- Nguyen-Dinh, P., Spencer, H.C., Chemangey-Masaba, S. & Churchill, F.C. 1982. Susceptibility of *Plasmodium falciparum* to pyrimethamine and sulfadoxine-pyrimethamine in Kisumu, Kenya. *Lancet*, 1(8276): 823-825.
- Nguyen-Dinh, P., Magloire, R., Chin, W. 1983 A simple field kit for the determination of drug susceptibility in *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.*, 32(3):452–455.
- Nguyen-Dinh, P., Greenberg, A.E., Kabote, N., Davachi, F., Groussard, B. & Embonga, B. 1987. *Plasmodium falciparum* in Kinshasa, Zaire: *in vitro* drug susceptibility studies. *Am. J. Trop. Med. Hyg.*, 37: 217–219.
- Nguyen-Dinh, P., Payne, D., Teklehaimanot, A., Ipenza, A.Z., Day, M.M. & Duverseau, Y.T. 1985a. Development of an *in vitro* microtest for determining the susceptibility of *Plasmodium falciparum* to sulfadoxine-pyrimethamine: laboratory investigations and field studies in Portau Prince, Haiti. *Bull. World Health Organ.*, 63(3):585–592.
- Nguyen-Dinh, P., Schwartz, I.K., Sexton, J.D., Bomboto, E., Botomwito, B., Kalisa, R., Ngimbi, N.P. & Wery M. 1985b. *In vivo* and *in vitro* susceptibility to chloroquine of *Plasmodium falciparum* in Kinshasa and Mbuji-Mayi, Zaire. *Bull World Health Organ*, 63: 325–330.
- Nguyen-Dinh, P., Magloire, R. & Chin, W. 1983. A simple field kit for the determination of drug susceptibility in *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.*, , 32:452–455.
- Nguyen-Pouplin, J., Tran, H., Tran, H., Phan, T.A., Dolecek, C. Farrar, J., Tran, T.H., Caron, P., Bodo, B. & Grellier, P. 2007. Antimalarial and cytotoxic activities of ethnopharmacologically selected medicinal plants from South Vietnam. *J. Ethnopharmacol.*, 109: 417–427.
- Nogady, T. 1985. *Medicinal Chemistry A Biochemical Approach*. Oxford University Press, New York.
- Nwaka, S. & Hudson, A. 2006. Innovative lead discovery strategies for tropical diseases. *Nat. Rev. Drug Discov.*, 5: 941-955.

- Olepu, S, Suryadevara, P.K., Rivas, K., Yokoyama, K., Verlinde, C.L.M.J., Chakrabarti, D., Voorhis, W.C.V. & Gelb, M.H. 2008. 2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. *Bioorg. Med. Chem. Lett.*, 18: 494-497.
- Olliaro, P. 2001. Mode of action and mechanism of resistance for antimalarial drugs. *Pharmacol. Ther.*, 89: 207-219.
- Ouattara, M., Wein, S., Calas, M., Hoang, Y.V., Viala, H. & Escaleb, R. 2007. Synthesis and antimalarial activity of new 1,12-bis-(N,N0-acetamidinyl)dodecane derivatives. *Bioorg. Med. Chem. Lett.*, 17: 593-596.
- Paul, J. 1975. *Cell and Tissue Culture*. Churchill Livingstone, London.
- Pearson, R. D. & Hewlett, E.L. 1998. Drugs effective against parasitic protozoal infections, dalam T.M. Brody, J. Larner & K.P. Minneman: *Human Pharmacology, Molecular to Clinical*, 773-785. Mosby-Year Book Inc., Missouri.
- Pradines, B., Rogier, C., Fusai, T., Tall, A., Trape, J. F. & Doury, J.C. 1996. Sensibilite *in vitro* de 85 isolats de *Plasmodium falciparum* dans la region de fatick, Senegal. *Med. Trop.*, 56:141-145.
- Pribadi, W. 2002. Parasit Malaria, dalam S. Gandahusada, H.D. Ilahude & W. Pribadi (Eds.): *Parasitologi Kedokteran*, edisi III, 171-192, Balai Penerbit FKUI, Jakarta.
- Purcell, W.P., Bass, G.E. & Clayton, J.M. 1973. *Strategy of Drug Design: A Guide to Biological Activity*. John Wiley and Sons, New York.
- Ramdja, M. 1997. Mekanisme resistensi *Plasmodium falciparum* terhadap klorokuin. *Medika*, 23(11): 873-5.
- Ramsay, A.R., Msaki, E.P., Kennedy, N., Ngowi, F.I. & Gillespie, S.H. 1996. Evaluation of the safety and efficacy of micronized halofantrine in the treatment of semi-immune patients with acute *Plasmodium falciparum* malaria. *Ann. Trop. Med. Parasitol.*, 90(5): 461-466.
- Rang, H.P., Dale, M.M., Ritter, J.M. & Moore, P.K. 2003. *Pharmacology*, 5thed., Churchill Livingstone, London.
- Reid, E. 1978. *Assay of Drugs and Other Trace Compounds in Biological Fluids*. North Holland Publishing Company, New York.

- Rekker, R.F. 1977. *The Hydrophobic Fragmental Constant*. Elsevier Scientific Publishing Co., Amsterdam.
- Richards, W.H.G. & Maples, B.K. 1979. Studies on *Plasmodium falciparum* in continuous cultivation. I. The effect of chloroquine and pyrimethamine on parasite growth and viability. *Ann. Trop. Med. Parasitol.*, 73: 99-108.
- Rieckman, K., Suebsaeng, L. & Rooney, W. 1987. Response of *Plasmodium falciparum* infections to pyrimethamine-sulfadoxine in Thailand. *Am. J. Trop. Med. Hyg.*, 37: 211-216.
- Ridley, R.G. 2002. Medical need, scientific opportunity and the drive for antimalarial drugs. *Nature*, 415: 686-693.
- Ritschel, W.A. 1976. *Handbook of Basic Pharmacokinetic*, 1st ed. Drug Intelligence Publications Inc., Hamilton.
- Ritschel, W.A. 1992. *Handbook of Basic Pharmacokinetic, Including Clinical Applications*, 4th ed. Drug Intelligence Publications Inc., Hamilton.
- Rosenthal, P.J. 2003. Antimalarial drug discovery: old and new approaches. *J. Exp. Biol.*, 206: 3735-3744.
- Roth, H.J., Blaschake, G. 1998. *Analisis Farmasi*, diterjemahkan oleh Sardjono Kisman dan Slamet Ibrahim. Gadjah Mada University Press, Yogyakarta.
- Sardjoko. 1993. *Rancangan Obat*. Gadjah Mada University Press, Yogyakarta.
- Scheibel, L.W. & Adler, A. 1981. Antimalarial activity of selected aromatic chelator: II. Substituted quinolines and quinolone-N-oxides. *Mol. Pharmacol.*, 20: 218-223.
- Scheibel, L.W. & Adler, A. 1982. Antimalarial activity of selected aromatic chelator: III. Substituted 8-hydroxyquinolines (oxines substituted in position 5 and 7 and oxines annealated in position 5,6 by an aromatic ring). *Mol. Pharmacol.*, 22: 140-144.
- Shargel, L., Wu-Pong, S. & Yu, A.B.C. 2005. *Applied Biopharmaceutics & Pharmacokinetics*. 5th ed., McGraw-Hill, New York.
- Sholikhah, E.N., Wijayanti, M.A., Nurani, L.H. & Mustofa. 2008. Stage specificity of Pasak Bumi root (*Eurycoma longifolia* Jack) isolate on *Plasmodium falciparum* cycles. *Med. J. Malaysia*, 63(Suppl A July): 98-99.

- Siegel, G.G. & Zeegers-Huyskens. 1989. Infrared study of the interaction between proton donors and 1,10-phenanthroline derivatives. *Spectrochimica Acta*, 45A(12): 1297-1304.
- Singh, C., Gupta, N. & Puri, S.K. 2005. Photooxygenation of 3-aryl-2-cyclohexenols: synthesis of a new series of antimalarial 1,2,4-trioxanes. *Tetrahedron Lett.*, 46: 205–207.
- Singh, C. Pandey, S., Kushwah, A. K. & Puri, S.K. 2008. New functionalized 1,2,4-trioxepanes: Synthesis and antimalarial activity against multi-drug resistant *P. yoelii* in mice. *Bioorg. Med. Chem. Lett.*, 18: 5190–5193.
- Siswandono & Soekardjo, B. 1998. *Prinsip-prinsip Rancangan Obat*. Airlangga University Press, Surabaya.
- Siswandono & Soekardjo, B. 2000. *Kimia Medisinal*. Airlangga University Press, Surabaya.
- Sitohy, M., Dalgarrondo, M., Nowoczin, M., Besse, B., Billaudel, S., Haertle, T. & Chobert, J. 2008. The effect of bovine whey proteins on the ability of poliovirus and coxsackie virus to infect Vero cell cultures. *Intern. Dairy J.*, 18: 658–668.
- Solomon, V.R., Puri, S.K., Srivastava, K. & Kattia, S. B. 2005. Design and synthesis of new antimalarial agents from 4-aminoquinoline. *Bioorg. Med. Chem.* 13: 2157–2165
- Somogyi, A., 1998, Clinical pharmacokinetics and dosing schedules., dalam T.M. Brody, J. Larner, & K.P. Minneman: *Human Pharmacology, Molecular to Clinical*, 47-64, Mosby-Year Book Inc, Missouri.
- Sowunmi, A., Falade, C.O., Oduola, A.M., Ogundahunsi, O.A., Fehintola, F.A., Gbotosho, G.O., Larcier, P., & Salako, L.A. 1998. Cardiac effects of halofantrine in children suffering from acute uncomplicated *falciparum* malaria. *Trans. R. Soc. Trop. Med. Hyg.*, 92(4): 446-448.
- Spencer, H.C., Masaba, S.C., Chulay, J.D. & Nguyen-Dinh, P. 1983. Field evaluation in Kenya of a 48-hour *in vitro* test for *Plasmodium falciparum* sensitivity to chloroquine. *Am. J. Trop. Med. Hyg.*, 32:916-921.
- Spilker, B. 1997. Drug development and approval process, dalam T.M. Speight & N.H.G. Holford, (Eds.): *Avery's Drug Treatment*, 4th ed., 423-449, Adis International, Aucland.

- Srinivas, S.D. & Puri, S.K. 2002. Time course of *in vitro* maturation of intra-erythrocytic malaria parasite: a comparison between *Plasmodium falciparum* and *Plasmodium knowlesi*. *Mem. Inst. Oswaldo Cruz*, 97(6): 901-903.
- Stein, G.E. 1998. Regulated drug development and usage, dalam T.M. Brody, J. Larner, & K.P. Minneman: *Human Pharmacology, Molecular to Clinical*, 903-908, Mosby-Year Book Inc, Missouri.
- Supargiyono, Jumina & Mustofa. 2006. Antimalaria baru turunan 1-Fenil-1,10-fenantrolin: Sintesis, kajian aktivitas antiplasmodium, toksisitas, farmakokinetika, mekanisme aksi dan formulasinya. *Laporan Penelitian Hibah Pascasarjana Angkatan II*, Departemen Pendidikan Nasional, Jakarta.
- Swarbrick, J. & Boyland, J.C. 2002a. *Encyclopedia of Pharmaceutical Technology*. 2nd ed., Vol. 1. Marcel Dekker, New York.
- Swarbrick, J. & Boyland, J.C. 2002b. *Encyclopedia of Pharmaceutical Technology*. 2nd ed., Vol. 2. Marcel Dekker, New York.
- Syafruddin, D., Krisin, Asih, P., Sekartuti, Dewi, R.M., Coutrier, F., Rozy, I.E., Susanti, A.I., Elyazar, I.R.F, Sutamihardja, A., Rahmat, A., Kinzer, M. & Rogers, W.O. 2009. Seasonal prevalence of malaria in West Sumba district, Indonesia. *Malaria J.*, 8(8): 1-8.
- Tambajong, E.H. 1999. Patobiologi malaria, dalam P.N. Harijanto (Ed.): *Malaria: Epidemiologi, Patogenesis, Manifestasi Klinis, & Penanganan*, EGC, Jakarta.
- Tambun, I. N.K. 2005. Beberapa parameter kimia fisik senyawa baru (1)-N-Etil-1,10-fenantrolinium sulfat, berkaitan dengan absorpsinya. *Skripsi*. Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Thaithong, S., Beale, G.H. & Chutmongkonkul, M. 1983. Susceptibility of *Plasmodium falciparum* to five drugs: an *in vitro* study of isolates mainly from Thailand. *Trans. Royal Soc. Trop. Med. and Hyg.*, 77: 228-231.
- Theis, J.G.W., Koren, G. 1997. Maternal and fetal clinical pharmacology, dalam T.M. Speight & N.H.G. Holford (eds.): *Avery's Drug Treatment*, 4th ed., 75-126, Adis International, Aucland.
- Ter-Kuile, F., White, N.J., Holloway, P., Pasvol, G., Krishna, S. 1993. *Plasmodium falciparum*: *in vitro* studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. *Exp. Parasitol.*, 76: 85-95.

- Tjokrosonto, S.. 1990. Resistensi terhadap obat antimalaria. *Berita Kedokteran Masyarakat*, VI(2):146-153.
- Tracy, J.W. & Webster, L.T. 2001. Drugs used in the chemotherapy of protozoal infections: malaria, dalam J.G. Hardman & L.E. Limbird (eds.): *Goodman & Gilman's, The Pharmacological Basis of Therapeutics*, 10th ed., 1069-1095. McGraw-Hill, New York.
- Trager, W. & Jensen, J.B. 1976. Human malaria parasites in continuous culture. *Science*, 193 (4254): 673-675.
- Tropical Diseases Center. 2004. *Proceeding* : Symposium of malaria control in Indonesia. TDC, Airlangga University, Surabaya.
- Tsafack A., Loyevsky, M., Ponka, P., Cabantchik, Z.I., 1996. Mode of action of iron (III) chelators as antimalarials IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. *J. Lab. Clin. Med.*, 127 : 574-582.
- Tuti, S. 1992. Resistensi *Plasmodium falciparum* terhadap beberapa obat anti malaria di Indonesia. *Cermin Dunia Kedokteran*, (76): 50-52.
- Udomsangpetch, R., Pipitaporn, B., Krishna, S., Angus, B., Pukrittayakamee, S., Bates, I., Supputamongkol, Y., Kyle, D.E. & White, N.J. 1996. Antimalarial drugs reduce cytoadherence and rosetting of *Plasmodium falciparum*. *J. Infect. Dis.*, 173(3) :691-698.
- Vial, H. & Ancelin, M.L., 1994, Recherches de nouvelles molecules antipaludieens: Une urgence, un espoir. *Pathol. Biol.*, 42, 138-144.
- Vathsala, P.G., Pramanik, A., Dhanasekaran, S., Ushadevi, C., Pillai, C.R., Subbarao, S.K., Ghosh, S.K., Tiwar, S.N., Sathyanarayan, T.S., Deshpande, P.R., Mishra, G.C., Ranjit, M.R., Dash, A.P., Rangarajan, P.N. & Padmanaban, G. 2004. Widespread occurrence of the *Plasmodium falciparum* chloroquine resistance transporter (Pfcrt) gene haplotype SVMNT in *P. falciparum* malaria in India. *Am. J. Trop. Med. Hyg.*, 70(3) : 256-259.
- Watson, D.G. 1999. *Pharmaceutical Analysis*. Churchill Livingstone, London.
- Wallace, R.J., Newbold, C.J., McKain, N. 1996. Inhibition by 1,10-phenantroline of the breakdown of peptides by rumen bacteria and protozoa. *J. Appl. Bacteriol.*, 80: 425-430.

- White, N.J. 1997. Minireview: assessment of the pharmacodynamic properties of antimalarial drugs *in vivo*. *Antimicrob. Agents Chemother.*, 41: 1413-1422.
- White, N.J., Krishna, S., Waller, D., Craddock, C., Kwiatkowski, D. & Brewster, D. 1989. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive *falciparum* malaria. *Lancet*, 2(8675): 1313-1316.
- WHO. 1998. *Roll back Malaria*. A global partnership. WHO, Geneva.
- WHO. 2008. *World Malaria Report 2008*. WHO, Geneva
- WHO. 2009. *World Malaria Report 2009*. WHO, Geneva
- Wilkinson, G.R. 2001. Pharmacokinetic, the dynamic of drug absorption, distribution, and elimination, dalam J.G. Hardman & L.E. Limbird (eds.): *Goodman & Gilman's, The Pharmacological Basis of Therapeutics*, 10th ed., 3-29. McGraw-Hill, New York.
- Winstanley, P.A., 2000, Chemotherapy for *falciparum* malaria: the Armoury, the problems and the prospects. *Parasitol. Today*, 16(4): 146-153.
- Winstanley, P. & Walley, T. 2002. *Medical Pharmacology*. 2nd ed., Churchill Livingstone, Edinburg.
- Wolff, M.E. 1980. *Burger's Medicinal Chemistry*, 4th ed. New York: John Wiley.
- Yapi. A.D., Valentin, A., Chezal, J.M., Chavignon, O., Chaillot, B., Gerhardt, R., Teulade, J.C. & Blache, Y. 2006. *In vitro* and *in vivo* antimalarial activity of derivatives of 1,10-phenanthroline framework. *Arch. Pharm. Chem. Life Sci.*, 339: 201-206.
- Yapi. A.D., Mustofa, Valentin, A., Chavignon, O., Teulade, J.C., Mallie, M., Chapat, J.P. & Blache, Y. 2000. New potential antimalarial agents: synthesis and biological activities of original diaza analogs phenanthrene. *Chem. Pharm. Bull.*, 48(12): 1886-1889.
- Yayon, A., Vande-Waa, J.A., Yayon, M., Geary, T.G. & Jensen, J.B. 1983. Stage-dependent effects of chloroquine on *Plasmodium falciparum in vitro*. *J. Protozool.*, 30: 642-647.
- Zalis, M.G., Wilson, C.M., Zhang, Y. & Wirth, D.F. 1993. Characterization of the *pfmdr2* gene for *P. falciparum*. *Mol. Biochem. Parasitol.* 62: 83-92.

- Zhang, Y., Asante, K.S. & Jung, A. 1986. Stage-dependent inhibition of chloroquine on *Plasmodium falciparum* in vitro. *J. Parasitol.* 72(6), 830-836.
- Zhu, S. Zhang, Q., Gudise, C., Meng, L., Wei, L., Smith, E. & Kong, Y. 2007. Synthesis and evaluation of naphthyridine compounds as antimalarial agents. *Bioorg.Med. Chem. Lett.* 17: 6101–6106.